DIVISLAB's weekly performance was disappointing, with a return of -2.54% and a max drawdown of the same magnitude. The stock's volatility was relatively high at 9.49%, indicating significant price fluctuations. Compared to its peers, DIVISLAB outperformed DRREDDY and CIPLA but underperformed SUNPHARMA in terms of returns. The stock's Sharpe ratio of -1.43 suggests that it was a relatively risky investment this week.

[Volatility: 9.49%]